BACKGROUND Surgery for obese patients carries a higher risk of anesthesia complications compared with surgery for nonobese patients.Thus,a safe and effective anesthesia strategy is necessary to improve the medical exp...BACKGROUND Surgery for obese patients carries a higher risk of anesthesia complications compared with surgery for nonobese patients.Thus,a safe and effective anesthesia strategy is necessary to improve the medical experience of such patients and ensure their safety.AIM To compared the effectiveness and safety of remimazolam besylate versus dexmedetomidine(DEX)in gastrointestinal surgery in obese patients.METHODS The study cohort included 60 obese patients undergoing gastrointestinal surgery between July 2021 and April 2023,comprising 30 patients who received DEX intervention(control group)and 30 patients who received remimazolam besylate intervention(research group).Heart rate(HR),respiratory rate(RR),mean arterial pressure(MAP),blood oxygen saturation(SpO_(2)),safety(nausea and vomiting,bradycardia,hypotension,and apnea),anesthesia and examination indices[induction time,anesthesia recovery time,and postanesthesia care unit(PACU)discharge time],sedation effect(Ramsay Sedation Scale),and postoperative pain visual analog scale were comparatively analyzed before anesthesia(T0),during anesthesia(T1),and after anesthesia(T2).RESULTS At T1,the research group showed significantly smaller changes in HR,RR,MAP,and SpO_(2) than the control group,with a significantly lower adverse reaction rate and shorter induction,anesthesia recovery,and PACU discharge times.Additionally,the intra-and postoperative Ramsay Sedation Scale scores were statistically higher in the research group than in the control group.CONCLUSION Remimazolam besylate was significantly more effective than DEX in gastrointestinal surgery in obese patients and had a higher safety profile and value in clinical promotion.展开更多
Objective:To investigate the effectiveness and efficiency of combining levamlodipine besylate and valsartan in the treatment of hypertension.Methods:This study selected 28 patients with hypertension as observation sub...Objective:To investigate the effectiveness and efficiency of combining levamlodipine besylate and valsartan in the treatment of hypertension.Methods:This study selected 28 patients with hypertension as observation subjects.The treatment duration ranged from January 2020 to June 2023.Using the random number table method,patients were divided into two groups.The control group received treatment with valsartan,while the observation group received a combination of valsartan and levamlodipine besylate.Therapeutic effects and safety were compared between the groups,and changes in the patient’s blood pressure and renal function index levels were assessed.Results:The total clinical effective rate of the observation group was significantly higher than that of the control group(P<0.05).The observation group demonstrated better diastolic blood pressure,systolic blood pressure,and renal function indicators compared to the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined treatment of levamlodipine besylate and valsartan in patients with hypertension showed significant clinical efficacy and holds broad application value.展开更多
A simple and sensitive kinetic spectrophotometric method has been developed and validated for determination of amlodipine besylate （AML）. The method was based on the condensation reaction of AML with 7-chloro-4-nitr...A simple and sensitive kinetic spectrophotometric method has been developed and validated for determination of amlodipine besylate （AML）. The method was based on the condensation reaction of AML with 7-chloro-4-nitro-2,1,3-benzoxadiazole in an alkaline buffer （pH 8.6） producing a highly colored product. The color development was monitored spectrophometrically at the maximum absorption λmax 470 nm. The factors affecting the reaction were studied and the conditions were optimized. The stoichiometry of the reaction was determined, and the reaction pathway was postulated. Moreover, both the activation energy and the specific rate constant （at 70 ℃） of the reaction were found to be 6.74 kcal mole-1 and 3.58 s -1, respectively. The initial rate and fixed time methods were utilized for constructing the calibration graphs lbr the determination of AML concentration. Under the optimum reaction conditions, the limits of detection and quantification were 0.35 and 1.05 ug/mL, respectively. The precision of the method was satisfactory; the relative standard deviations were 0.85-1.76%. The proposed method was successfully applied to the analysis of AML in its pure form and tablets with good accuracy; the recovery percentages ranged from 99.55 ± 1.69% to 100.65 ±1.48%. The results were compared with that of the reported method.展开更多
目的系统评价艾司氯胺酮与苯磺酸瑞马唑仑联合使用对内镜逆行胰胆管造影术(ERCP)患者的影响。方法检索中国知网、维普、万方、PubMed、Web of science、Embase及Cochrance图书馆的数据库,从建库到2023年3月发表的艾司氯胺酮联合苯磺酸...目的系统评价艾司氯胺酮与苯磺酸瑞马唑仑联合使用对内镜逆行胰胆管造影术(ERCP)患者的影响。方法检索中国知网、维普、万方、PubMed、Web of science、Embase及Cochrance图书馆的数据库,从建库到2023年3月发表的艾司氯胺酮联合苯磺酸瑞马唑仑用于ERCP的随机对照试验(RCTs)。试验组采用艾司氯胺酮复合苯磺酸瑞马唑仑的麻醉方案,对照组采用其他静脉麻醉药物联合使用方案。由互不关联的2名研究者根据纳入排除标准对文献进行仔细筛选,使用Review Manager 5.4软件进行统计分析。结果纳入6项RCTs,共532例患者。与其他麻醉药物联合使用方案比较,艾司氯胺酮联合苯磺酸瑞马唑仑组患者发生低血压、呼吸抑制等不良事件的概率更低(RR=0.29,95%CI 0.17~0.50;RR=0.18,95%CI 0.08~0.38)。结论采用艾司氯胺酮联合苯磺酸瑞马唑仑能减少患者ERCP中的不良事件发生概率,是一种更平稳、安全的麻醉方法。展开更多
目的对比高血压患者分别应用苯磺酸左旋氨氯地平片与苯磺酸氨氯地平片治疗的临床疗效。方法90例高血压患者,通过随机数字表法分为对照组(45例)、观察组(45例)。给予对照组患者苯磺酸氨氯地平片治疗,给予观察组患者苯磺酸左旋氨氯地平片...目的对比高血压患者分别应用苯磺酸左旋氨氯地平片与苯磺酸氨氯地平片治疗的临床疗效。方法90例高血压患者,通过随机数字表法分为对照组(45例)、观察组(45例)。给予对照组患者苯磺酸氨氯地平片治疗,给予观察组患者苯磺酸左旋氨氯地平片治疗。比较两组临床疗效、不良反应发生率及治疗前后动态血压[24 h收缩压(SBP)、舒张压(DBP)]、心率(HR)、血清学指标[同型半胱氨酸(Hcy)、B型尿钠肽(BNP)、白细胞介素-6(IL-6)]。结果观察组临床总有效率95.56%(43/45)高于对照组的88.89%(40/45),但差异无统计学意义(P>0.05)。治疗前及治疗后两组组间24 h SBP、24 h DBP、HR比较差异无统计学意义(P>0.05);观察组与对照组治疗后24 h SBP、24 h DBP分别为(144.58±9.06)、(85.26±6.84)mm Hg(1 mm Hg=0.133 kPa)与(146.24±8.58)、(86.47±8.65)mm Hg,均低于治疗前的(164.76±10.47)、(100.95±10.94)mm Hg与(165.87±11.56)、(101.35±11.16)mm Hg(P<0.05);观察组与对照组治疗后HR与治疗前比较差异无统计学意义(P>0.05)。治疗前及治疗后两组组间BNP、Hcy、IL-6水平比较差异无统计学意义(P>0.05);相比治疗前,观察组与对照组治疗后BNP、Hcy、IL-6水平均降低(P<0.05)。治疗后,观察组不良反应发生率2.22%明显低于对照组的17.78%(P<0.05)。结论高血压患者使用苯磺酸左旋氨氯地平片与苯磺酸氨氯地平片治疗,其治疗效果及对血压的控制、血清学指标的影响相近,但苯磺酸左旋氨氯地平片不良反应发生率更低,因此临床可根据患者实际情况进行选择。展开更多
文摘BACKGROUND Surgery for obese patients carries a higher risk of anesthesia complications compared with surgery for nonobese patients.Thus,a safe and effective anesthesia strategy is necessary to improve the medical experience of such patients and ensure their safety.AIM To compared the effectiveness and safety of remimazolam besylate versus dexmedetomidine(DEX)in gastrointestinal surgery in obese patients.METHODS The study cohort included 60 obese patients undergoing gastrointestinal surgery between July 2021 and April 2023,comprising 30 patients who received DEX intervention(control group)and 30 patients who received remimazolam besylate intervention(research group).Heart rate(HR),respiratory rate(RR),mean arterial pressure(MAP),blood oxygen saturation(SpO_(2)),safety(nausea and vomiting,bradycardia,hypotension,and apnea),anesthesia and examination indices[induction time,anesthesia recovery time,and postanesthesia care unit(PACU)discharge time],sedation effect(Ramsay Sedation Scale),and postoperative pain visual analog scale were comparatively analyzed before anesthesia(T0),during anesthesia(T1),and after anesthesia(T2).RESULTS At T1,the research group showed significantly smaller changes in HR,RR,MAP,and SpO_(2) than the control group,with a significantly lower adverse reaction rate and shorter induction,anesthesia recovery,and PACU discharge times.Additionally,the intra-and postoperative Ramsay Sedation Scale scores were statistically higher in the research group than in the control group.CONCLUSION Remimazolam besylate was significantly more effective than DEX in gastrointestinal surgery in obese patients and had a higher safety profile and value in clinical promotion.
文摘Objective:To investigate the effectiveness and efficiency of combining levamlodipine besylate and valsartan in the treatment of hypertension.Methods:This study selected 28 patients with hypertension as observation subjects.The treatment duration ranged from January 2020 to June 2023.Using the random number table method,patients were divided into two groups.The control group received treatment with valsartan,while the observation group received a combination of valsartan and levamlodipine besylate.Therapeutic effects and safety were compared between the groups,and changes in the patient’s blood pressure and renal function index levels were assessed.Results:The total clinical effective rate of the observation group was significantly higher than that of the control group(P<0.05).The observation group demonstrated better diastolic blood pressure,systolic blood pressure,and renal function indicators compared to the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined treatment of levamlodipine besylate and valsartan in patients with hypertension showed significant clinical efficacy and holds broad application value.
文摘A simple and sensitive kinetic spectrophotometric method has been developed and validated for determination of amlodipine besylate （AML）. The method was based on the condensation reaction of AML with 7-chloro-4-nitro-2,1,3-benzoxadiazole in an alkaline buffer （pH 8.6） producing a highly colored product. The color development was monitored spectrophometrically at the maximum absorption λmax 470 nm. The factors affecting the reaction were studied and the conditions were optimized. The stoichiometry of the reaction was determined, and the reaction pathway was postulated. Moreover, both the activation energy and the specific rate constant （at 70 ℃） of the reaction were found to be 6.74 kcal mole-1 and 3.58 s -1, respectively. The initial rate and fixed time methods were utilized for constructing the calibration graphs lbr the determination of AML concentration. Under the optimum reaction conditions, the limits of detection and quantification were 0.35 and 1.05 ug/mL, respectively. The precision of the method was satisfactory; the relative standard deviations were 0.85-1.76%. The proposed method was successfully applied to the analysis of AML in its pure form and tablets with good accuracy; the recovery percentages ranged from 99.55 ± 1.69% to 100.65 ±1.48%. The results were compared with that of the reported method.
文摘目的对比高血压患者分别应用苯磺酸左旋氨氯地平片与苯磺酸氨氯地平片治疗的临床疗效。方法90例高血压患者,通过随机数字表法分为对照组(45例)、观察组(45例)。给予对照组患者苯磺酸氨氯地平片治疗,给予观察组患者苯磺酸左旋氨氯地平片治疗。比较两组临床疗效、不良反应发生率及治疗前后动态血压[24 h收缩压(SBP)、舒张压(DBP)]、心率(HR)、血清学指标[同型半胱氨酸(Hcy)、B型尿钠肽(BNP)、白细胞介素-6(IL-6)]。结果观察组临床总有效率95.56%(43/45)高于对照组的88.89%(40/45),但差异无统计学意义(P>0.05)。治疗前及治疗后两组组间24 h SBP、24 h DBP、HR比较差异无统计学意义(P>0.05);观察组与对照组治疗后24 h SBP、24 h DBP分别为(144.58±9.06)、(85.26±6.84)mm Hg(1 mm Hg=0.133 kPa)与(146.24±8.58)、(86.47±8.65)mm Hg,均低于治疗前的(164.76±10.47)、(100.95±10.94)mm Hg与(165.87±11.56)、(101.35±11.16)mm Hg(P<0.05);观察组与对照组治疗后HR与治疗前比较差异无统计学意义(P>0.05)。治疗前及治疗后两组组间BNP、Hcy、IL-6水平比较差异无统计学意义(P>0.05);相比治疗前,观察组与对照组治疗后BNP、Hcy、IL-6水平均降低(P<0.05)。治疗后,观察组不良反应发生率2.22%明显低于对照组的17.78%(P<0.05)。结论高血压患者使用苯磺酸左旋氨氯地平片与苯磺酸氨氯地平片治疗,其治疗效果及对血压的控制、血清学指标的影响相近,但苯磺酸左旋氨氯地平片不良反应发生率更低,因此临床可根据患者实际情况进行选择。
